Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.33 |
| ▸ | PLA2G4A | P47712 | 3/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.32 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.32 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.32 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25801860 | 0.85 | GAA (0.36) | GAALPAR1LPAR2LPAR3PLA2G4A | |
| SCHEMBL25801535 | 0.73 | TSHR (0.31) | GAA | |
| SCHEMBL25801865 | 0.72 | NOS1 (0.30) | — | |
| SCHEMBL25801531 | 0.71 | TSHR (0.31) | — | |
| SCHEMBL25802002 | 0.70 | MMP8 (0.33) | — | |
| SCHEMBL25801863 | 0.70 | TSHR (0.32) | — | |
| SCHEMBL28842631 | 0.67 | HSP90AA1 (0.31) | ENPP2LPAR1LPAR2LPAR3BIRC2 | |
| SCHEMBL25801858 | 0.67 | NPSR1 (0.43) | — | |
| SCHEMBL25801743 | 0.67 | LMNA (0.41) | GAA | |
| SCHEMBL7099471 | 0.66 | GAA (0.59) | GAAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | GAA 1592/4885ENPP2 132/4885LPAR1 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.